Civica says the first in its line of low-cost insulins could be available for purchase as soon as early 2024.

As 340B Providers Grapple with High Cost Diabetes Medicine, Civica Plans to Make and Distribute Generic Insulins Priced as Low as $30

Nonprofit drug manufacturer Civica announced this morning that it plans to manufacture and distribute insulins that, once approved, will be available to people with diabetes at no more than $30 per vial and no more than $55 for a box of five pen cartridges—significantly less than insulins now on the market, it says.

“The availability of affordable insulins will benefit people with diabetes who have been forced to choose between life sustaining medicines and living expenses, particularly those uninsured or underinsured who often pay the most out of pocket for their medications,” Civica said in a March 3 news release.

Nonprofit drug manufacturer CivicaRx announced this morning that it plans to manufacture and distribute insulins that, once approved, will be available to people with diabetes at no more than $30 per vial and no more than $55 for a box of five pen cartridges—significantly less than insulins now on the market, it says.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report